Biohaven Pharmaceutical Q3 EPS $(1.75) Up From $(1.91) YoY

Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(1.75) per share. This is a 8.38 percent increase over losses of $(1.91) per share from the same period last year.

byBill Haddad

November 9, 2022

1 minute read

Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(1.75) per share. This is a 8.38 percent increase over losses of $(1.91) per share from the same period last year.

Lemonade Sells Metromile’s Enterprise Business Solutions Platform To EIS; Terms Not Disclosed

By Benzinga Newsdesk

Today, 9:25 AM

Lemonade (NYSE:LMND), the insurance company powered by AI and social impact, today announced the close of its divestiture of Metromile's Enterprise Business Solutions (EBS) to digital insurance platform, EIS.

LMND

Keybanc Initiates Coverage On Franco-Nevada with Overweight Rating, Announces Price Target of $156

By vishwanath@benzinga.com

Today, 9:25 AM

Keybanc analyst Adam Josephson initiates coverage on Franco-Nevada (NYSE:FNV) with a Overweight rating and announces Price Target of $156.

FNV

Pharming Provides Update On European Medicines Agency Regulatory Review Of Leniolisib For APDS In Europe; Decided To Shift Its Assessment Of The Marketing Authorisation Application For Leniolisib To A Standard Review Timetable

By Happy Mohamed

Today, 9:25 AM

EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands, Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the

PHAR

Cathie Wood Buys Another $800K In This Elon Musk-Led SpaceX’s 3D Printing Partner

By Rachit Vats

Today, 9:25 AM

Cathie Wood-led Ark Investment Management on Wednesday bought 102,790 shares, estimated to be worth about $814,097, in Velo3D Inc (NYSE: VLD), the 3D company that went public earlier this month via a merger with special purpose acquisition company Jaws Spitfire Ac

ARKQ

Biohaven Pharmaceutical Q3 EPS $(1.75) Up From $(1.91) YoY

Related Posts

Lemonade Sells Metromile’s Enterprise Business Solutions Platform To EIS; Terms Not Disclosed

Keybanc Initiates Coverage On Franco-Nevada with Overweight Rating, Announces Price Target of $156

Pharming Provides Update On European Medicines Agency Regulatory Review Of Leniolisib For APDS In Europe; Decided To Shift Its Assessment Of The Marketing Authorisation Application For Leniolisib To A Standard Review Timetable

Cathie Wood Buys Another $800K In This Elon Musk-Led SpaceX’s 3D Printing Partner